167 related articles for article (PubMed ID: 17087601)
1. Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Doležalová R; Haluzík MM; Bošanská L; Lacinová Z; Kasalová Z; Stulc T; Haluzík M
Physiol Res; 2007; 56(6):741-748. PubMed ID: 17087601
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
[TBL] [Abstract][Full Text] [Related]
3. Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.
Anderlová K; Dolezalová R; Housová J; Bosanská L; Haluzíková D; Kremen J; Skrha J; Haluzík M
Physiol Res; 2007; 56(5):579-586. PubMed ID: 17184146
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
5. Correlation between circulating adhesion molecules and resistin levels in hypertensive type-2 diabetic patients.
Lozano-Nuevo JJ; Estrada-Garcia T; Vargas-Robles H; Escalante-Acosta BA; Rubio-Guerra AF
Inflamm Allergy Drug Targets; 2011 Feb; 10(1):27-31. PubMed ID: 21184654
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics.
Ghanim H; Dhindsa S; Aljada A; Chaudhuri A; Viswanathan P; Dandona P
J Clin Endocrinol Metab; 2006 Sep; 91(9):3553-8. PubMed ID: 16804037
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.
Yin WH; Jen HL; Chen JW; Lin SJ; Young MS
Diabetes Metab; 2006 Jun; 32(3):229-35. PubMed ID: 16799399
[TBL] [Abstract][Full Text] [Related]
8. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Yang WS; Jeng CY; Wu TJ; Tanaka S; Funahashi T; Matsuzawa Y; Wang JP; Chen CL; Tai TY; Chuang LM
Diabetes Care; 2002 Feb; 25(2):376-80. PubMed ID: 11815513
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
[TBL] [Abstract][Full Text] [Related]
10. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.
Jung HS; Youn BS; Cho YM; Yu KY; Park HJ; Shin CS; Kim SY; Lee HK; Park KS
Metabolism; 2005 Mar; 54(3):314-20. PubMed ID: 15736108
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
12. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease.
Derosa G; D'Angelo A; Romano D; Maffioli P
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272312
[TBL] [Abstract][Full Text] [Related]
14. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.
Basu A; Jensen MD; McCann F; Nandy D; Mukhopadhyay D; McConnell JP; Rizza RA
Endocr Pract; 2007; 13(2):147-52. PubMed ID: 17490928
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.
Yilmaz MI; Sonmez A; Caglar K; Gok DE; Eyileten T; Yenicesu M; Acikel C; Bingol N; Kilic S; Oguz Y; Vural A
Endocrine; 2004 Dec; 25(3):207-14. PubMed ID: 15758247
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
18. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
20. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]